SELLAS Life Sciences Group Announces Initiation Of Galinpepimut-S Phase 1 Clinical Trial In Combination With PD-1 Checkpoint Inhibitor For Patients With Ovarian Cancer /PRNewswire/ — SELLAS Life Sciences Group , a development-stage biopharmaceutical company with its main focus on developing innovative products to treat cancers and central nervous system diseases, today announced the initiation of a Phase 1 clinical trial to evaluate the safety and efficacy of SELLAS’s galinpepimut-S in combination with nivolumab , Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor.
